Skip to content

Aerobic Exercise Addition to Cognitive Behavioural Treatment in Impotence Metabolic-syndrome Drinkers

Is There a Benefit of Aerobic Exercise Addition to Cognitive Behavioural Treatment in Heavy Drinking Men With Impotence and Metabolic Syndrome?

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07277673
Enrollment
40
Registered
2025-12-11
Start date
2025-10-10
Completion date
2026-02-15
Last updated
2025-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heavy Drinking, Impotence, Metabolic Syndrome

Brief summary

Cognitive Behavioural Treatment is used as treatment for Heavy Drinking, Impotence, and Metabolic Syndrome. The efficacy of adding aerobic training to this treatment is not tested till now.

Detailed description

Forty men with Heavy Drinking, Impotence, and Metabolic Syndrome will be included. catogorization will be performed to assign them to group number I or group number II. Every group will involve/contain twenty males. Both groups will receive Cognitive Behavioural Treatment (30 minute per the session , three times/week, for 12 weeks). Also, Group number I will also adminsiter supervised aerobic training (walking on electrical treamill, 50 minute per the session , three times/week, for 12 weeks).

Interventions

BEHAVIORALaerobci physical training and cognitive behavioural treatment

Twenty men with Heavy Drinking, Impotence, and Metabolic Syndrome receive Cognitive Behavioural Treatment (30 minute per the session , three times/week, for 12 weeks). Also, men will also adminsiter supervised aerobic training (walking on electrical treamill, 50 minute per the session, three times/week, for 12 weeks).

BEHAVIORALCognitive behavioural treatment

Twenty men with Heavy Drinking, Impotence, and Metabolic Syndrome will receive Cognitive Behavioural Treatment (30 minute per the session , three times/week, for 12 weeks)

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
35 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* heavy drinking men (forty) * men who complain metabolic syndrome * men who complain impotence

Exclusion criteria

* cardiac problems * renal or hepatic or respiratory or neurogenic diseases,

Design outcomes

Primary

MeasureTime frameDescription
international index of erectile functionit will be measured after 12 weeksit contain 5 questions that will assess penile erectile functions

Secondary

MeasureTime frameDescription
waist circumferenceIt will be measured after 12 weeksit will be assessed at ubmlilicus by a tape
blood systolic pressureIt will be measured after 12 weeksit will be assessed via sphygmonameter
blood diastolic pressureit will be measured after 12 weeksit will be assessed via sphygmonameter
triglyceridesIt will be measured after 12 weeksit will be assessed in plasma
high density lipoproteinsIt will be measured after 12 weeksit will be assessed via plasma
blood glucoseIt will be measured after 12 weeksit will assessed vin fasting plasma
body mass indexIt will be measured after 12 weeksit will be assessed on empty stomach and empty bladder and empty bowel
negative affectIt will be measured after 12 weeksa subscomponent of Alcohol-abstinence self-efficacy questioannire
Positive and social affectIt will be measured after 12 weeksa subscomponent of Alcohol-abstinence self-efficacy questioannire
physical and other concernsIt will be measured after 12 weeksa subscomponent of Alcohol-abstinence self-efficacy questioannire
craving and urgesIt will be measured after 12 weeksa subscomponent of Alcohol-abstinence self-efficacy questioannire
Depression, Anxiety and Stress ScaleIt will be measured after 12 weeksthe total score of this questioannaire that contin 21 questions will be scored
Alcohol abstinence self-efficacyIt will be measured after 12 weeksthe total score of this questionaire will be estimated

Countries

Egypt

Contacts

Primary ContactAli MA Ismail, lecturer
ali.mohamed@pt.cu.edu.eg01005154209
Backup ContactAli Mohamed, lecturer
allooka2012@gmail.com01031321109

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026